Drug Discovery

BullFrog AI, Sage Group partner to develop oncology assets

Digital technology company BullFrog AI and Sage Group have entered into a strategic partnership to develop oncology assets.

Talem, Xyphos sign agreement for potential cancer therapeutic candidates

ImmunoPrecise Antibodies (IPA) subsidiary, Talem Therapeutics has entered into a research collaboration and licence option agreement with Astellas Pharma’s wholly-owned subsidiary, Xyphos Biosciences.

Macomics signs collaboration deal with Ono Pharmaceutical

Macomics and Ono Pharmaceutical have entered into a global collaboration deal for the discovery and development of macrophage-targeting antibody therapy for cancer.

Dewpoint, Novo Nordisk to identify drug candidates for diabetic complications

Dewpoint Therapeutics has formed a research and development partnership with Novo Nordisk for identifying drug candidates to treat insulin resistance and diabetic complications.

invoX Pharma completes acquisition of F-star Therapeutics for $161m

invoX Pharma, a UK-based biopharmaceutical company and a wholly-owned subsidiary of Sino Biopharmaceutical, has closed the acquisition of F-star Therapeutics, a clinical-stage biopharmaceutical company focusing on bispecific antibodies in immunotherapy.

Tempus, Pfizer partner for cancer drug development

Tempus has unveiled a multi-year strategic partnership with Pfizer for advancing the development of cancer drugs.

Alchemab, MDC receive grant to develop Huntington’s disease therapy

Biotechnology company Alchemab Therapeutics and Medicines Discovery Catapult (MDC) have received $2.06m (£1.7m) grant from Innovate UK to accelerate the development of disease modifying therapy to treat Huntington’s disease.

Gilgamesh raises funds to advance treatments for mental health

Biotechnology company Gilgamesh Pharmaceuticals has raised $39m in Series B financing round, led by Prime Movers Lab, for advancing treatments for mental health.

Innovent and LG Chem sign agreement for gout disease therapy Tigulixostat

Innovent Biologics and LG Chem Life Sciences have signed an agreement for the latter’s late-stage novel non-purine xanthine oxidase inhibitor (XOI) Tigulixostat for the chronic management of hyperuricemia in individuals with gout disease.